HRS-4642 (Not yet branded)
Other Medications
Description
HRS-4642 is an experimental compound being evaluated in colorectal cancer treatment, specifically in the neoadjuvant setting for locally advanced disease. Based on its association with KRAS biomarkers in clinical trials, this agent appears to target molecular pathways relevant to KRAS-driven tumors. The drug is currently being tested in umbrella trial designs that evaluate targeted therapies based on specific tumor genetic profiles in colorectal cancer patients.
Mechanism of Action
HRS-4642 likely targets cellular pathways downstream or associated with KRAS signaling, though the exact molecular mechanism has not been fully disclosed in available clinical data. The drug's inclusion in KRAS biomarker-driven trials suggests it may interfere with oncogenic signaling cascades that promote tumor growth and survival in KRAS-mutated colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.